| Literature DB >> 34184000 |
Stephanie Baggio1,2, Frederique Jacquerioz3,4, Julien Salamun3, Hervé Spechbach3, Yves Jackson3.
Abstract
INTRODUCTION: The COVID-19 pandemic has excessively affected socially and economically deprived groups of population. There is a dearth of empirical evidence about the effect of policies regulating access to care for such groups. This study aims to document the impact of an equity-based strategy to facilitate access to COVID-19 testing during the initial phase of the pandemic.Entities:
Keywords: COVID-19; Equity; Homeless; Testing; Undocumented migrants
Year: 2021 PMID: 34184000 PMCID: PMC8214821 DOI: 10.1016/j.jmh.2021.100051
Source DB: PubMed Journal: J Migr Health ISSN: 2666-6235
Sociodemographic and clinical characteristics of the study participants.
| Participants | ||||
|---|---|---|---|---|
| All ( | Underserved ( | General ( | P-value | |
| Sociodemographics and clinical characteristics | ||||
| Age | 42.3 (14.9) | 39.8 (12.7) | 42.5 (15.0) | .012 |
| Gender (female) | 1764 (53.5) | 111 (51.6) | 1653 (53.6) | .575 |
| Clinical risk factors | ||||
| ≥ 1 chronic disease | 1116 (33.8) | 64 (29.8) | 1052 (34.1) | .194 |
| Multimorbidity (≥ 2 chronic diseases) | 284 (8.6) | 15 (7.0) | 269 (8.7) | .379 |
| Exposure to SARS-CoV-2 | ||||
| Return from a highly endemic region | 251 (7.6) | 11 (5.1) | 240 (7.8) | .157 |
| Contact with a confirmed case | 954 (28.9) | 63 (29.3) | 891 (28.9) | .898 |
| Access to and uptake of testing | ||||
| Testing within 3 days after first symptoms’ occurrence | 1401 (45.5) | 79 (40.5) | 1322 (45.8) | .149 |
| Number of symptoms | 4.3 (2.2) | 4.2 (2.4) | 4.3 (2.2) | .409 |
| Testing during the first month of the program | 1684 (51.0) | 112 (52.1) | 1512 (51.0) | .751 |
| SARS-CoV-2 nucleic acid testing | ||||
| Positive | 797 (24.2) | 69 (32.1) | 728 (23.6) | .005 |
Participants with asymptomatic presentation (n = 72) and missing value for the date of onset of symptoms (n = 148) were excluded.
Sociodemographic and clinical characteristics of participants with a positive SARS-CoV-2 test.
| Participants | ||||
|---|---|---|---|---|
| All ( | Underserved ( | General ( | P-value | |
| Age | 43.1 (14.4) | 41.9 (13.4) | 43.2 (14.5) | .495 |
| Gender (female) | 396 (49.7) | 35 (50.7) | 361 (49.6) | .857 |
| ≥ 1 chronic disease | 227 (28.5) | 20 (29.0) | 2017 (28.4) | .923 |
| Multimorbidity (≥ 2 chronic diseases) | 53 (6.7) | 4 (5.8) | 49 (6.7) | .766 |
| Testing within 3 days after first symptoms’ occurrence | 340 (44.4) | 24 (36.4) | 416 (45.1) | .172 |
| Number of symptoms | 4.5 (2.1) | 4.9 (2.4) | 4.5 (2.0) | .139 |
| testing during the first month of the program | 305 (38.3) | 29 (42.0) | 276 (37.9) | .502 |
| Hospitalization | 65 (8.2) | 7 (10.3) | 58 (8.0) | .509 |
Participants with asymptomatic presentation (n = 7) and missing value for the date of onset of symptoms (n = 24) were excluded.